文献速递临床生化临床免疫质量管理与危急值

Atellica IM分析仪上增强型肝纤维化(ELF)检测的分析性能

Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer.
PubMed 文献 · Clin Chim Acta · 2023-06-29

该研究按照临床与实验室标准协会(CLSI)方案,在Atellica IM分析仪上评估ELF检测三项血清标志物(HA、PIIINP、TIMP-1)及ELF评分的分析性能。结果显示检出能力、精密度、线性等参数均达到预设要求,重复性≤5.4% CV,实验室内精密度≤8.5% CV,ELF评分重复性≤0.6% CV,与ADVIA Centaur ELF检测相关性良好(r=0.997)。

要点

  • HA、PIIINP、TIMP-1三项检测的LoB、LoD、LoQ均达到预设要求
  • 三项检测重复性≤5.4% CV,实验室内精密度≤8.5% CV
  • Atellica IM与ADVIA Centaur ELF检测相关性良好(r=0.997)

核心结论

  • ELF检测及ELF评分在Atellica IM分析仪上的分析性能验证结果优良,可用于常规临床使用。

研究设计与样本

  • 按照临床与实验室标准协会(CLSI)方案,评估检出能力(空白限、检出限、定量限)、精密度、干扰、线性、钩状效应及ELF参考区间。

主要发现

  • HA的LoB为1.00 ng/mL、LoD为2.00 ng/mL、LoQ为3.00 ng/mL。
  • PIIINP的LoB为0.50 ng/mL、LoD为0.75 ng/mL、LoQ为1.00 ng/mL。
  • TIMP-1的LoB为3.0 ng/mL、LoD为4.0 ng/mL、LoQ为5.0 ng/mL。
  • 三项检测重复性≤5.4% CV,实验室内精密度≤8.5% CV;ELF评分重复性≤0.6% CV,实验室内精密度≤1.3% CV,再现性≤1.1% CV。
  • Atellica IM ELF与ADVIA Centaur ELF检测相关性良好(y = 1.01x - 0.22,r = 0.997)。

关键数值与推荐

  • 所有参数均达到预设要求:HA(LoB 1.00 ng/mL、LoD 2.00 ng/mL、LoQ 3.00 ng/mL)。
  • PIIINP(LoB 0.50 ng/mL、LoD 0.75 ng/mL、LoQ 1.00 ng/mL)。
  • TIMP-1(LoB 3.0 ng/mL、LoD 4.0 ng/mL、LoQ 5.0 ng/mL)。
  • 三项检测重复性≤5.4% CV,实验室内精密度≤8.5% CV。
  • ELF评分重复性≤0.6% CV,实验室内精密度≤1.3% CV,再现性≤1.1% CV。

临床怎么用

  • 该验证结果支持在Atellica IM分析仪上常规开展ELF检测及ELF评分用于肝纤维化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Enhanced Liver Fibrosis (ELFTM) Test comprises 3 direct serum markers of fibrosis-hyaluronic acid (HA), amino-terminal pro-peptide of type III procollagen (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1)-whose results are combined in an algorithm to generate the ELF score. Outside the U.S., the ELF Test and score are CE marked for assessment of liver fibrosis severity in patients with signs, symptoms, or risk factors of chronic liver disease to support diagnosis of fibrosis staging or prognosis for likelihood of progression to cirrhosis and liver-related clinical events. In the U.S., the FDA granted de novo marketing authorization to aid prognostic evaluation of disease progression (to cirrhosis and liver-related clinical events) in nonalcoholic steatohepatitis patients with advanced liver fibrosis. We describe the analytical performance of the ELF analytes and score on the Atellica® IM Analyzer. METHODS: Clinical and Laboratory Standards Institute protocols were followed for detection capability (limits of blank [LoB], detection [LoD], and quantitation [LoQ]), precision, interference, linearity, hook effect, and ELF reference interval. RESULTS: All parameters met predetermined requirements: HA (LoB 1.00 ng/mL, LoD 2.00 ng/mL, LoQ 3.00 ng/mL); PIIINP (LoB 0.50 ng/mL, LoD 0.75 ng/mL, LoQ 1.00 ng/mL); TIMP-1 (LoB 3.0 ng/mL, LoD 4.0 ng/mL, LoQ 5.0 ng/mL). Across the 3 assays, repeatability was ≤5.4% CV; within-lab precision was ≤8.5% CV. ELF score repeatability was ≤0.6% CV, within-lab precision ≤1.3% CV, and reproducibility ≤1.1% CV. Good correlation was obtained between the Atellica IM ELF and ADVIA Centaur ELF Tests (y = 1.01x - 0.22, r = 0.997). Assays were linear across analytical measuring ranges. CONCLUSIONS: Analytical performance validation results for the ELF Test and ELF score were excellent making the test acceptable for routine clinical use.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Palladino A, Gee M, Shalhoub V, et al. Analytical performance of the Enhanced Liver Fibrosis (ELF) Test on the Atellica IM Analyzer. Clin Chim Acta. 2023. PMID: 37390944. doi:10.1016/j.cca.2023.117461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。